Aussie stem cell firms jump on Japan fast-track
25 November, 2013 by Dylan Bushell-EmblingRegeneus (ASX:RGS) and Mesoblast (ASX:MSB) both plan to take advantage of a new expedited regulatory pathway for regenerative medicine products in Japan.
ResMed wins temporary German injunctions in patent suits
22 November, 2013 by Dylan Bushell-EmblingA German court has ordered a Taiwanese and a Chinese medical device manufacturer to stop selling some devices alleged to infringe ResMed (ASX:RMD) patents without a further court order.
TGA streamlines adverse event reporting
21 November, 2013AusBiotech has welcomed the TGA's announcement that it has introduced a streamlined way for sponsors to submit adverse event reports for medicines and vaccines, to ease the administrative burden of the 7000-8000 annual reports.
Mesoblast MPCs improve function in heart failure
20 November, 2013 by Dylan Bushell-EmblingDuring a recent trial, heart failure patients on assisted circular support demonstrated improved cardiac function when injected with Mesoblast (ASX:MSB) MPCs at time of LVAD implantation.
Avita facing 'first strike' on executive pay
20 November, 2013 by Dylan Bushell-EmblingAvita Medical's (ASX:AVH) two largest shareholders plan to vote against the company's remuneration report, with Bioscience Managers calling for the replacement of the chairman and CEO.
Government to cut R&D incentive for big business
19 November, 2013The government plans to remove access to the R&D tax incentive for big business.
Quarterly payments of R&D tax incentive stalled in review
19 November, 2013AusBiotech is urging the Coalition government to deliver on its pro-business rhetoric and pass the R&D Tax Incentive's quarterly payments legislation. The much-anticipated measure has been earmarked as "further consultation required" in Treasurer Joe Hockey's plan to deal with the backlog of unlegislated tax measures: 'Restoring Integrity in the Australian Tax System'.
IDT breaks into generic drugs with US filing
18 November, 2013 by Dylan Bushell-EmblingPharmaceutical manufacturing company IDT Australia (ASX:IDT) has filed the first of a series of planned marketing applications for generic drugs, with a US filing for chemotherapy temozolomide.
Regeneus gets US green light for cancer vaccine
14 November, 2013 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has received US regulatory approval to commercialise a cell-based canine cancer vaccine in the US, giving it an accelerated pathway to launch.
Simavita to list on Toronto exchange
14 November, 2013 by Susan WilliamsonMedical device company Simavita is planning to raise AU$15 million via an IPO, with the aim of listing on Canada’s Toronto Stock Exchange.
AusBiotech releases calendar for 2014 major events
14 November, 2013The latest calendar for AusBiotech’s line-up of major life sciences events brings you all your favourites and some new additions, amounting to a broad range of networking, learning and sponsorship opportunities. Save the dates now for 2014 …
iSonea CEO to resign in May
13 November, 2013 by Dylan Bushell-EmblingiSonea (ASX:ISN) will hunt for an international sales exec to replace its outgoing CEO, while Starpharma (ASX:SPL) has named the person slated to replace its long-serving chairman.
Medical device sector's time to shine
12 November, 2013 by Dylan Bushell-EmblingThe medical device segment was the star performer of the Australian life sciences sector during Q413, and the stage is set for further growth, PwC's latest BioForum report says.
Mesoblast MPCs may extend stroke treatment window
12 November, 2013 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) detailed preclinical research suggests that its proprietary MPCs could improve recovery in ischemic stroke patients, even when injected up to seven days post stroke.
CSL named most respected life science company
12 November, 2013Biotechnology major CSL was last week named Australia's most respected 'chemical/life sciences' company, appearing for the first time in the top 10 companies in the Australian Financial Review's 'Boss' magazine annual study.
